NASDAQ$NPCE
Neuropace Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
NeuroPace's financial performance for Q1 2021 was reported, demonstrating growth in revenue and initial implant revenue.
NeuroPace reported a 12% increase in total revenue, reaching $11.2 million, and a 23% increase in initial implant revenue, totaling $8.1 million for the first quarter of 2021. The company completed an initial public offering, raising approximately $105 million in net proceeds and issued 2021 total revenue guidance of approximately $47 million, representing 14% growth compared to 2020.
- Total revenue reached $11.2 million, a 12% increase year-over-year.
- Initial implant revenue increased by 23% to $8.1 million compared to the prior year.
- The company successfully completed an IPO, raising approximately $105 million.
- 2021 total revenue guidance is approximately $47 million, representing 14% growth.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$11.2M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
NeuroPace provided financial guidance for the full year 2021, projecting total revenue of approximately $47 million, representing 14% growth compared to the prior year period.
Tailwinds
- Total revenue of approximately $47 million, representing growth of 14% compared to prior year period.
- Initial implant revenue of approximately $36 million, representing growth of 29% compared to prior year period.
- Initial implant revenue guidance of $36 million includes a small clinical study revenue contribution.
Headwinds
- Ongoing challenges and uncertainties due to the COVID-19 pandemic and its impact on physician and patient behavior
- Replacement implant revenue of approximately $11 million, representing a decline of 16% compared to prior year period.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.0%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | +0.8% | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro